Ripretinib monotherapy (advanced GIST, ≥4L after imatinib + sunitinib + regorafenib)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-RIPRETINIB |
|---|
| ID | REG-RIPRETINIB-GIST-4L |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-INVICTUS SRC-NCCN-GIST-2025 |
Notes
Switch-pocket inhibitor of broad spectrum of KIT and PDGFRA mutations (exon 9, 11, 13, 14, 17, 18; PDGFRA exon 12, 14, 18 except D842V). INVICTUS (Phase III, n=129, ripretinib 150 mg vs placebo, 4L+ GIST after imatinib + sunitinib + regorafenib) — mPFS 6.3 vs 1.0 mo (HR 0.15, p<0.0001); mOS 15.1 vs 6.6 mo (HR 0.36); ORR 9.4% vs 0%; favorable safety profile vs prior 4L options. INTRIGUE Phase III (ripretinib vs sunitinib 2L) was NEGATIVE — sunitinib remains 2L SOC; ripretinib position unchanged at 4L+. Pending Co-Lead sign-off.
Used By
Indication
IND-GIST-4L-RIPRETINIB- IND-GIST-4L-RIPRETINIB